GRAL

GRAIL, Inc. focuses on early cancer detection through the development of a multi-cancer early detection (MCED) test called Galleri®. The company utilizes next-generation sequencing, clinical studies, and machine learning to identify multiple cancer types before symptoms appear. GRAIL operates clinical laboratories and collaborates with healthcare systems and pharmaceutical companies to enhance cancer screening and improve detection rates, particularly among underserved populations.